Cargando…

The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program

BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Berkness, Tyler, Carrillo, M. C., Sperling, R., Petersen, R., Aisen, P., Flournoy, C., Snyder, H., Raman, R., Grill, J. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019089/
https://www.ncbi.nlm.nih.gov/pubmed/34101785
http://dx.doi.org/10.14283/jpad.2021.12
_version_ 1783674310457556992
author Berkness, Tyler
Carrillo, M. C.
Sperling, R.
Petersen, R.
Aisen, P.
Flournoy, C.
Snyder, H.
Raman, R.
Grill, J. D.
author_facet Berkness, Tyler
Carrillo, M. C.
Sperling, R.
Petersen, R.
Aisen, P.
Flournoy, C.
Snyder, H.
Raman, R.
Grill, J. D.
author_sort Berkness, Tyler
collection PubMed
description BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigators. DESIGN: The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a novel multidisciplinary clinical trial training program funded by the National Institute on Aging and the Alzheimer’s Association with two educational tracks. The Professionals track includes individuals who fill a broad variety of roles including clinicians, study coordinators, psychometricians, and other study professionals who wish to further their knowledge and advance their careers in ADRD trials. The Fellowship track includes current and future principal investigators and focuses on the design, conduct and analysis of ADRD clinical trials. SETTING: The 2020 inaugural iteration of IMPACT-AD was held via Zoom. PARTICIPANTS: Thirty-five trainees (15 Fellowship track; 20 Professionals track) were selected from 104 applications (34% acceptance rate). Most (n=25, 71%) identified as female. Fifteen (43%) were of a non-white race; six (18%) were of Hispanic ethnicity; eight (23%) indicated they were the first person in their family to attend college. MEASUREMENTS: Participants completed daily evaluations as well as pre- and post-course assessments of learning. RESULTS: Across topic areas, >90% of trainees evaluated their change in knowledge based on the lectures as “very much” or “somewhat increased.” The mean proportion correct responses in pre- and post-course assessments increased from 55% to 75% for the Professionals track and from 54% to 78% for the Fellowship track. CONCLUSIONS: IMPACT-AD successfully launched a new training opportunity amid a global pandemic that preliminarily achieved the goals of attracting a diverse cohort and providing meaningful training. The course is funded through 2025.
format Online
Article
Text
id pubmed-8019089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80190892021-04-06 The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program Berkness, Tyler Carrillo, M. C. Sperling, R. Petersen, R. Aisen, P. Flournoy, C. Snyder, H. Raman, R. Grill, J. D. J Prev Alzheimers Dis Original Research BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigators. DESIGN: The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a novel multidisciplinary clinical trial training program funded by the National Institute on Aging and the Alzheimer’s Association with two educational tracks. The Professionals track includes individuals who fill a broad variety of roles including clinicians, study coordinators, psychometricians, and other study professionals who wish to further their knowledge and advance their careers in ADRD trials. The Fellowship track includes current and future principal investigators and focuses on the design, conduct and analysis of ADRD clinical trials. SETTING: The 2020 inaugural iteration of IMPACT-AD was held via Zoom. PARTICIPANTS: Thirty-five trainees (15 Fellowship track; 20 Professionals track) were selected from 104 applications (34% acceptance rate). Most (n=25, 71%) identified as female. Fifteen (43%) were of a non-white race; six (18%) were of Hispanic ethnicity; eight (23%) indicated they were the first person in their family to attend college. MEASUREMENTS: Participants completed daily evaluations as well as pre- and post-course assessments of learning. RESULTS: Across topic areas, >90% of trainees evaluated their change in knowledge based on the lectures as “very much” or “somewhat increased.” The mean proportion correct responses in pre- and post-course assessments increased from 55% to 75% for the Professionals track and from 54% to 78% for the Fellowship track. CONCLUSIONS: IMPACT-AD successfully launched a new training opportunity amid a global pandemic that preliminarily achieved the goals of attracting a diverse cohort and providing meaningful training. The course is funded through 2025. Springer International Publishing 2021-04-02 2021 /pmc/articles/PMC8019089/ /pubmed/34101785 http://dx.doi.org/10.14283/jpad.2021.12 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle Original Research
Berkness, Tyler
Carrillo, M. C.
Sperling, R.
Petersen, R.
Aisen, P.
Flournoy, C.
Snyder, H.
Raman, R.
Grill, J. D.
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title_full The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title_fullStr The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title_full_unstemmed The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title_short The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
title_sort institute on methods and protocols for advancement of clinical trials in adrd (impact-ad): a novel clinical trials training program
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019089/
https://www.ncbi.nlm.nih.gov/pubmed/34101785
http://dx.doi.org/10.14283/jpad.2021.12
work_keys_str_mv AT berknesstyler theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT carrillomc theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT sperlingr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT petersenr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT aisenp theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT flournoyc theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT snyderh theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT ramanr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT grilljd theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT berknesstyler instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT carrillomc instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT sperlingr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT petersenr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT aisenp instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT flournoyc instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT snyderh instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT ramanr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram
AT grilljd instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram